]]> Understanding the genetic causes of rare diseases supports drug development. Credit: Shutterstock.
Developing drugs to treat rare diseases is fraught with challenges; these range from trying to recruit from tiny patient populations to fill much-need clinical trials to the complex reimbursement landscape for these innovative, and often bespoke, therapies. However, as scientists improve their understanding of the genetic causes of many rare conditions and regulators explore new reimbursement options, pharma companies and smaller biotech firms are increasingly being empowered to address more of these tricky indications.
In this context, could 2020 be a breakthrough year for patients with rare diseases? Here are three case studies of companies on the verge of having treatments for rare diseases approved Rocket and Fanconi anaemia, PTC Therapeutics and aromatic l-amino acid decarboxylase (AADC) deficiency and, finally, Amryt and epidermolysis bullosa.
Fanconi anaemia (FA) is a rare paediatric inherited diseasecharacterised by bone marrow failure and predisposition to cancer, in the words of Rocket Pharmas CEO Gaurav Shah. Caused by a mutation in the FANC genes, patients with Fanconi experience bone marrow failure as they are unable to create new blood cells.
The current standard of care for Fanconi is a stem cell transplant, but Shah explains the risks involved with these pioneering procedures.
While these transplants do prolong patients lives, the procedure is incredibly difficult and is associated with a high potential for graft-versus-host disease, he says. Stem cell transplants can also lead to an even higher risk of head and neck cancer risk for Fanconi patients; almost everyone with FA who undergoes this procedure dies in their 30s.
Rocket wants to change this situation with its lentiviral vector gene therapy, RP-L102. It is specifically for Fanconi-A, which Shah explains is the most common form of the disease. He adds that the therapy contains patient-derived haematopoietic stem cells that have been generally modified to contain a functional copy of FANCA gene, a mutation which causes Fanconi-A.
RP-L102 is currently in a global registrational Phase IIA study, which has been efficacious and safe in patients so far. The data demonstrate that a single dose of RP-L102 leads to both genetic and functional correction as measured by a progressive increase in corrected peripheral blood and bone marrow cells, says Shah. Most importantly, this treatment can be administered without a conditioning regimen [of chemotherapy and radiation]. [This] means we may be able to treat patients as a preventative measure before bone marrow failure occurs, like a vaccine, with a single dose administration early in life.
Based on these promising signals, RP-L102 has received all accelerated regulatory tools from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is hoping to complete its biologics license applications and marketing authorisation applications (MAA) to the two regulators within the next few years.
To overcome challenges facing Rocket in the development of RP-L102, Shah explains the company worked to improve upon its own expertise in rare diseases by working with world-class research and development partners, as well immersing itself within patient communities to learn more about their treatment needs.
Slightly further along the drug approval journey is PTC Therapeutics AADC deficiency drug, PTC-AADC, for which the company recently submitted an MAA to the EMA. The company expects full EMA approval towards the end of 2020 and to treat the first patients either in the first or second quarter of 2021.
PTC acquired PTC-AADC, alongside other gene therapy assets, when it bought rare central nervous system-focused Agilis Biotherapeutics in July 2018, PTCs EMEA and Asia Pacific senior vice-president and general manager Adrian Haigh explains.
AADC deficiency is a rare condition caused by a mutation in the DDC gene, which leads to issues with the AADC enzyme and subsequent reductions in the production of dopamine. Children suffering with AADC deficiency fail to reach neurological and development milestones and have a high risk of death early in life. The only current approach to treating the condition is through dopamine agonists, which Haigh notes are largely ineffective.
The particular approach developed by Agilis, [which is] unlike other forms of gene therapy, involves delivering a very small dose of gene therapy directly into the affected, post-mitotic cells, Haigh says. The rationale is that once youve delivered the drug to post-mitotic cells, which are not dividing, it is going to stay there for a long time.
Other advantages include a reduced chance of significant immune reaction and since the dose is smaller, the treatment could overcome some of the manufacturing issues facing other gene therapies. PTC has decided to bring PTC-AADCs manufacturing in house so they are not reliant on third parties schedules and capacities.
PTCs MAA for its AADC deficiency gene therapy is based on two clinical trials of 26 patients in total. Haigh explains the company has mapped motor milestones, and he noted that in advisory boards with payers theyve been incredibly impressed by our videos showing children progressing from lying flat on their backs to walking around.
He notes that in this case, it is certainly not ethical to drill a hole in a patients head and inject a virus containing a placebo and instead PTC has successfully completed a single-arm trial by comparing with patients natural history. Regulators need to be open to novel clinical trial design, particularly in rare diseases where you have ethical problems, Haigh argues.
The company had to abandon a previous drug in development because they could not agree an economic and deliverable clinical trial design with the FDA.
One of the main challenges that faced PTC in the development of PTC-AADC was diagnosis. Haigh explains they found a lot of patients have been misdiagnosed with either cerebral palsy or epilepsy so the company launched a free genetic testing programme. This also allowed them to find patients to recruit into the trial and estimate the number of patients with AADC deficiency who might be able to benefit from this gene therapy.
Epidermolysis bullosa (EB) is a group of rare skin conditions caused by genetic mutations in the genes that encode for the proteins of the skin, particularly in collagen VII.
There are currently no approved treatments for this condition, EB charity DEBRAs UK branch director of research Caroline Collins notes the condition is managed by regular changing of dressings and the lancing of blisters.
EB is characterised by blisters and wounds on the skin; these wounds are extremely painful and can cover huge areas of the patients body, such as their whole back or entire legs. However, Collins explains these are not like the kinds of wounds you get with ulcers or burns, and they move continuously.
As well as making it incredibly challenging for patients to deal with these never-healing wounds, it also makes it difficult for drug developers to find and establish accepted clinical trial endpoints centred on wound healing. DEBRA is therefore advocating for natural history to be considered in clinical trial designs, Collins explains.
Despite these challenges, UK drug company Amryt is hoping to submit authorisation applications to the FDA and EMA by the end of 2021 for its EB drug, AP101. The company has repurposed the topical gel created for burns wounds to treat EB. It is made from a combination of an extract from the bark of the birch tree and pure sunflower oil, the companys chief medical officer Dr Mark Sumeray explains.
AP101 is currently being studied in a Phase III study Amryt claim this is the biggest global EB trial ever undertaken and has been granted rare paediatric disease designation from the FDA.
Although the current results are blinded, Sumeray explains a recent analysis by an independent data monitoring board found that the firm only needed to increase the number of patients slightly, suggesting that at this point in time, the data would have looked encouraging. Too small a patient population makes it hard for efficacy to be statistically significant.
Since Amryts AP101 may be the first drug approved for EB, Collins emphasises it is important that the company has productive conversations with regulators about the specific challenges of EB. This will help to set the ground for others to follow and further transform the lives of EB patients.
It is clear that Amryt is committed to EB because the company in-licensed a second EB candidate, a topical gene therapy called AP103 in 2018.
Sumeray explains: We have invested a lot of time and effort in the development, not only of the lead product, but also of relationships with physicians and scientists working in EB. If we can figure out how to successfully bring products to the market and have them reimbursed, then all of that knowledge can applied again.
- Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients - Newswise - April 9th, 2020
- First Stem Cell Clinical Trial for Protection Against COVID-19 Approved by FDA - HospiMedica - April 9th, 2020
- Moving toward Nonchemotherapy-Based Approaches in Follicular Lymphoma - Cancer Network - April 9th, 2020
- Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS - P&T Community - April 9th, 2020
- Immunotherapy After Chemotherapy Improves Outcomes in Metastatic Bladder Cancer - Curetoday.com - April 9th, 2020
- Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome - Yahoo... - April 9th, 2020
- UCSD To Advance Stem Cell Therapies in New Space Station Lab - Technology Networks - April 9th, 2020
- Convalescent plasma therapy useful in treating COVID-19 - Anadolu Ajans - April 9th, 2020
- Stempeutics partners with Global Consortium of cell therapy companies - BSI bureau - April 9th, 2020
- DNA Repair Gene-Related CHIP Is a Marker for Worse Outcomes in Patients With Lymphoma - Cancer Therapy Advisor - April 9th, 2020
- Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Financial Post - April 8th, 2020
- SNUH team finds causal gene of inherited retinal disorder - Korea Biomedical Review - April 8th, 2020
- FDA Accepts IND for NK Cell Therapy CYNK-001 to Treat Patients with COVID-19 - Cancer Network - April 8th, 2020
- Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen - BioSpace - April 8th, 2020
- Beam Therapeutics Licenses SIRION Biotech's LentiBOOST Technology for its CAR-T pipeline - Business Wire - April 8th, 2020
- COVID-19 Impact on Stem Cell Therapy Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 - Science... - April 8th, 2020
- Nurses life-saving stem cell transplant leaves her with an addiction to Monster Munch just like her don - The Sun - April 8th, 2020
- Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) - Science In Me - April 8th, 2020
- CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) - GlobeNewswire - April 8th, 2020
- Coronavirus Update: Cell Therapy Reportedly Appears Promising To Beat COVID-19 - International Business Times - April 7th, 2020
- panCELLa receives research and development support for cell therapy - Yahoo Finance - April 7th, 2020
- Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress - Yahoo Finance - April 7th, 2020
- Stempeutics partners with Global Consortium of cell therapy companies - Express Healthcare - April 7th, 2020
- CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) - BioSpace - April 7th, 2020
- Stem Cell Network Warns that Claims of Stem Cell Treatments for COVID-19 Are Unfounded and Misleading - Benzinga - April 2nd, 2020
- FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS - Yahoo Finance - April 2nd, 2020
- Cork man shares hacks for isolation that stopped him from 'going insane' - Echo Live - April 2nd, 2020
- Notice Regarding Business Alliance Between Sanbio and Ocumension in the Research, Development and Commercialization of Innovative Stem Cell Therapies... - April 2nd, 2020
- Designer, injectable gels to prevent transplanted Schwann cell loss during spinal cord injury therapy - Science Advances - April 2nd, 2020
- David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer - GlobeNewswire - April 2nd, 2020
- Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) - Publicist360 - April 2nd, 2020
- CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality... - April 2nd, 2020
- Stem Cell Network Warns that Claims of Stem Cell Treatments for COVID-19 Are Unfounded and Misleading - GlobeNewswire - March 31st, 2020
- ElevateBio reels in $170M to push 6 cell, gene therapy programs - FierceBiotech - March 31st, 2020
- Stem Cells, Nerves Found to Interact in Cancer Progression - Pharmacy Times - March 31st, 2020
- Canine Stem Cell Therapy Market by Players, Types and Applications with In-Depth Research On Industry Size ... - The Financial News Daily - March 31st, 2020
- Blood donors in high demand - Dominion Post - The Dominion Post - March 29th, 2020
- Reversing The Ageing Process With Stem Cell Therapy - Version Weekly - March 29th, 2020
- Positive Opinion from European Medicines Agency for Sanofi's Isatuximab in R/R Multiple Myeloma - OncoZine - March 28th, 2020
- Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Business... - March 28th, 2020
- Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio... - March 28th, 2020
- HIV/AIDS cure: Second patient confirmed HIV-free and here's the treatment that cured him - EconoTimes - March 28th, 2020
- Donald Trump Is Using An Insanely Sketchy Newsletter To Find Campaign Donors - The Union Journal - March 28th, 2020
- Stem Cell Alopecia Treatment Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 -... - March 28th, 2020
- Canine Stem Cell Therapy Market Dynamics, Segments and Supply Demand 2029 - Packaging News 24 - March 28th, 2020
- Global Stem Cell and Gene Therapy Biological Testing Market (2019 to 2025) - Potential Growth Opportunities and Areas of Focus -... - March 27th, 2020
- Non-Profit Offers Free Stem Cell Therapy to Veterans - Pain News Network - March 27th, 2020
- Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Yahoo Finance - March 27th, 2020
- Kalytera Therapeutics: improving bone marrow transplants with CBD - Health Europa - March 27th, 2020
- A new way to study HIV's impact on the brain - Penn: Office of University Communications - March 27th, 2020
- HKBU Collaborates with Golden Meditech to Conduct Cell Therapy Research - QS WOW News - March 27th, 2020
- Medigene Provides Results for Fiscal Year 2019 and Outlook - Yahoo Finance - March 26th, 2020
- What Does It Mean to Be Immunocompromised? - Dana-Farber Cancer Institute - March 26th, 2020
- Oscar Saxelby-Lee gets 'super cells' after having stem cell transplant from dad to fight off cancer - Ledbury Reporter - March 26th, 2020
- Study Shows Development of Young Cells Could be New Option in Cancer Care - BioSpace - March 26th, 2020
- Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer - Yahoo Finance - March 26th, 2020
- Uni kit to help with virus tests - Kent Online - March 26th, 2020
- Old human cells rejuvenated with stem cell technology - Stanford Medical Center Report - March 25th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- YOUR HEALTH: A rare disease that hardens the skin - WQAD.com - March 25th, 2020
- Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL - Cancer Therapy Advisor - March 25th, 2020
- Stem Cell Alopecia Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bandera County Courier - March 24th, 2020
- Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Yahoo... - March 24th, 2020
- Clinical trial to find effective Covid-19 treatments gets underway - Nursing Times - March 24th, 2020
- Pipeline: Investigational Therapies for COVID-19 - The Cardiology Advisor - March 24th, 2020
- Mentoring is a gift, asking for help a blessing - The Jewish News of Northern California - March 24th, 2020
- The Global Autologous Cell Therapy Market is expected to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period... - March 24th, 2020
- The Forefront of Treating Hair Loss in Women - Yahoo Lifestyle - March 24th, 2020
- Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn's Leronlimab, Bringing the Total to Four Patients - Associated... - March 24th, 2020
- Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures | DNA RNA and Cells |... - March 24th, 2020
- Platelet Rich Plasma and Stem Cell Alopecia Treatment size in terms of volume and value 2019-2022 - Daily Science - March 24th, 2020
- Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates - GlobeNewswire - March 24th, 2020
- Stem Cell Alopecia Treatment Market Booming by Size, Revenue and Top Growing Companies APEX Biologix, Belgravia Center, RepliCel, Riken Research... - March 20th, 2020
- His Immune System Went Out of Whack. The Usual Treatment Didnt Work. Why? - The New York Times - March 18th, 2020
- China reports new progress in drug, therapies against Covid-19 - The Star Online - March 18th, 2020
- Imfinzi in Combination with Standard-of-Care Chemotherapies Improves Survival in Lung Cancer - Curetoday.com - March 18th, 2020
- What Are Drug Prevention and Treatment Options for COVID-19? - Pharmacy Times - March 18th, 2020
- Tessa Therapeutics to launch first CAR-T therapy for Hodgkin's lymphoma (HL) - BSA bureau - March 18th, 2020
- Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, MD, Ph.D., as New Chief Executive Officer - BioSpace - March 18th, 2020
- Fate Therapeutics: Potential Catalysts Ahead - Seeking Alpha - March 18th, 2020